Health Care & Life Sciences » Pharmaceuticals | United Laboratories International Holdings Ltd.

United Laboratories International Holdings Ltd. | Balance Sheet

Fiscal year is January-December. All values HKD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,975
2,218
2,144
3,144
2,561
2,434
Total Accounts Receivable
3,031
2,752
2,042
2,051
2,832
3,404
Inventories
1,272
1,418
1,415
1,072
1,408
1,670
Other Current Assets
264
230
154
130
114
123
Total Current Assets
6,542
6,617
5,755
6,397
6,915
7,631
Net Property, Plant & Equipment
10,272
10,122
9,615
8,498
8,551
7,750
Total Investments and Advances
2,421
1,796
1,638
1,346
1,009
820
Intangible Assets
65
58
100
164
185
165
Other Assets
283
282
263
251
264
269
Total Assets
19,600
18,918
17,408
16,669
16,940
16,652
ST Debt & Current Portion LT Debt
5,548
5,254
4,926
4,031
1,709
Accounts Payable
1,938
2,070
1,683
1,697
2,210
Income Tax Payable
33
63
34
32
117
Other Current Liabilities
2,344
1,528
1,815
1,719
1,714
Total Current Liabilities
9,863
8,914
8,458
7,479
5,749
Long-Term Debt
2,165
2,163
1,420
2,506
4,121
Deferred Taxes
965
726
675
627
418
Total Liabilities
13,011
11,846
10,591
10,626
10,306
Common Equity (Total)
6,482
6,969
6,719
5,973
6,533
Total Shareholders' Equity
6,482
6,969
6,719
5,973
6,533
Total Equity
6,482
6,969
6,719
5,973
6,533
Liabilities & Shareholders' Equity
19,600
18,918
17,408
16,669
16,940
Non-Equity Reserves
107
103
98
70
102

About United Laboratories International Holdings

View Profile
Address
6 Fuk Wang Street
Hong Kong
Hong Kong
Employees -
Website http://www.tul.com.cn
Updated 07/08/2019
United Laboratories International Holdings Ltd. operates as an investment company, which engages in the manufacturing and sale of medicines, and the bulk and intermediate products used to produce finished goods. It operates through the following segments: Intermediate Products, Bulk Medicine, and Finished Products. The Intermediate Products segment offers two major products, such as T-Octylammonium Clavulanate and 6-APA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.